pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2025-35-1-86-94pulmo-4683Research ArticleОБЗОРЫREVIEW«Навигатор» по хронической обструктивной болезни легких – инновационный инструмент для врача и пациента“COPD Navigator” – an innovative tool for doctor and patienthttps://orcid.org/0000-0002-1171-2746БудневскийА. В.BudnevskyA. V.

Будневский Андрей Валериевич – д. м. н., профессор, заведующий кафедрой факультетской терапии

394036, Воронеж, ул. Студенческая, 10, тел.: (473) 263-81-30

Andrey V. Budnevsky, Doctor of Medicine, Professor, Honored Inventor of the Russian Federation, Head of the Department of Faculty Therapy

ul. Studencheskaya 10, Voronezh, 394622, tel.: (473) 263-81-30 

budnev@list.ruhttps://orcid.org/0000-0002-5999-2150АвдеевС. Н.AvdeevS. N.

Авдеев Сергей Николаевич – д. м. н., профессор, академик Российской академии наук, заведующий кафедрой пульмонологии Института клинической медицины имени Н.В.Склифосовского; главный внештатный специалист-пульмонолог Министерства здравоохранения Российской Федерации; директор Национального медицинского исследовательского центра по профилю «Пульмонология»

119991, Москва, ул. Трубецкая, 8, стр. 2, тел.: (495) 708-35-76 

Sergey N. Avdeev, Doctor of Medicine, Professor, Academician of Russian Academy of Sciences, Head of the Department of Pulmonology, N.V.Sklifosovsky Institute of Clinical Medicine; Chief Freelance Pulmonologist of the Ministry of Health of the Russian Federation; Director of the National Medical Research Center for Pulmonology

ul. Trubetskaya 8, build. 2, Moscow, 119991, tel.: (495) 708-35-76 

serg_avdeev@list.ruhttps://orcid.org/0000-0002-8545-6255ОвсянниковЕ. С.OvsyannikovE. S.

Овсянников Евгений Сергеевич – д. м. н., профессор кафедры факультетской терапии

394036, Воронеж, ул. Студенческая, 10, тел.: (473) 263-81-30 

Evgeniy S. Ovsyannikov, Doctor of Medicine, Professor, Department of Faculty Therapy

ul. Studencheskaya 10, Voronezh, 394622, tel.: (473) 263-81-30 

ovses@yandex.ruhttps://orcid.org/0000-0003-4128-6044ФейгельманС. Н.FeigelmanS N.

Фейгельман Софья Николаевна – ассистент кафедры факультетской терапии

394036, Воронеж, ул. Студенческая, 10, тел.: (473) 263-81-30 

Sofia N. Feigelman, Assistant, Department of Faculty Therapy 

ul. Studencheskaya 10, Voronezh, 394622, tel.: (473) 263-81-30 

s.feygelman@gmail.comФедеральное государственное бюджетное образовательное учреждение высшего образования «Воронежский государственный медицинский университет имени Н.Н.Бурденко» Министерства здравоохранения Российской ФедерацииРоссияFederal State Budgetary Educational Institution of Higher Education “N.N.Burdenko Voronezh State Medical University” of the Ministry of Healthcare of the Russian FederationRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М.Сеченова Министерства здравоохранения Российской Федерации (Сеченовский Университет)РоссияFederal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)Russian Federation2025210120253518694Copyright © Будневский А.В., Авдеев С.Н., Овсянников Е.С., Фейгельман С.Н., 20252025Будневский А.В., Авдеев С.Н., Овсянников Е.С., Фейгельман С.Н.Budnevsky A.V., Avdeev S.N., Ovsyannikov E.S., Feigelman S.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/4683

Хроническая обструктивная болезнь легких (ХОБЛ) является одним из самых распространенных заболеваний дыхательной системы во всем мире. Правильное лечение данного заболевания подразумевает учет многих дополнительных факторов, что может вызывать трудности у врачей первичного звена. В 2023 г. Международной группой первичной медико-санитарной помощи при респираторных заболеваниях (International Primary Care Respiratory Group – IPCRG) разработан новый инструмент для врачей первичного звена, позволяющий быстро определить тактику лечения и проконсультировать больных ХОБЛ по поводу основных причин и последствий заболевания. Целью работы явилась оценка возможности инновационного инструмента «Колесо» ХОБЛ в обеспечении интеграции усилий врача и пациента для достижения контроля над заболеванием. Заключение. Использование инструмента «Колесо» ХОБЛ может обеспечить своевременное назначение лекарственных препаратов в соответствии с конкретным клиническим случаем, а также значительно улучшить приверженность пациентов терапии. В результате следует ожидать улучшения качества жизни и прогноза у больных ХОБЛ.

Chronic obstructive pulmonary disease (COPD) is one of the most common respiratory diseases in the world. Correct treatment of this disease shall account for many additional factors, which can be difficult for primary care physicians. In 2023, the International Primary Care Respiratory Group (IPCRG) developed a new tool for primary care physicians – the COPD “Wheel” that allows for determining the treatment tactics quickly and consulting COPD patients about the main causes and consequences of the disease. The aim of the work was to evaluate whether the innovative tool ensures the integration of physician and patient efforts in achieving COPD control. Conclusion. The COPD Wheel tool ensures timely prescription of drugs suitable for a specific clinical case, as well as significantly improves the patient’s adherence to therapy. As a result, patients with COPD should be expected to have improved quality of life and prognosis.

хроническая обструктивная болезнь легкихтактика веденияполиморбидностьchronic obstructive pulmonary diseasemanagementpolymorbidityReferencesGlobal Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2025 Report. Available at: https://goldcopd.org/2025-gold-report/ [Accessed: December 12, 2024].Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2025 Report. Available at: https://goldcopd.org/2025-gold-report/ [Accessed: December 12, 2024].Министерство здравоохранения Российской Федерации. Клинические рекомендации. Хроническая обструктивная болезнь легких. 2024. Доступно на: https://cr.minzdrav.gov.ru/view-cr/603_3 [Дата обращения: 20.12.24].Ministry of Health of the Russian Federation. [Clinical recommendations. Chronic obstructive pulmonary disease]. 2024. Available at: https://cr.minzdrav.gov.ru/view-cr/603_3 [Accessed: December 20, 2024] (in Russian).Effing T.W., Vercoulen J.H., Bourbeau J. et al. Definition of a COPD self-management intervention: International Expert Group consensus. Eur. Respir. J. 2016; 48 (1): 46–54. DOI: 10.1183/13993003.00025-2016.Effing T.W., Vercoulen J.H., Bourbeau J. et al. Definition of a COPD self-management intervention: International Expert Group consensus. Eur. Respir. J. 2016; 48 (1): 46–54. DOI: 10.1183/13993003.00025-2016.Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022; 32 (3): 356–392. DOI: 10.18093/0869-0189-2022-32-3-356-392.Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Chronic obstructive pulmonary disease: federal clinical guidelines for diagnosis and treatment]. Pul'monologiya. 2022; 32(3): 356–392. DOI: 10.18093/0869-0189-2022-32-3-356-392 (in Russian).Soriano J.B., Visick G.T., Muellerova H. et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128 (4): 2099–2107. DOI: 10.1378/chest.128.4.2099.Soriano J.B., Visick G.T., Muellerova H. et al. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005; 128 (4): 2099–2107. DOI: 10.1378/chest.128.4.2099.Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–1257. DOI: 10.1183/09031936.00133805.Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur. Respir. J. 2006; 28 (6): 1245–1257. DOI: 10.1183/09031936.00133805.Fabbri L.M., Luppi F., Beghé B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31 (1): 204–212. DOI: 10.1183/09031936.00114307.Fabbri L.M., Luppi F., Beghé B., Rabe K.F. Complex chronic comorbidities of COPD. Eur. Respir. J. 2008; 31 (1): 204–212. DOI: 10.1183/09031936.00114307.Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2024 Report. Available at: https://goldcopd.org/2024-gold-report/ [Accessed: December 26, 2024].Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2024 Report. Available at: https://goldcopd.org/2024-gold-report/ [Accessed: December 26, 2024].Ялтонский В., Ялтонская А., Сирота Н., Московченко Д. Психометрические характеристики русскоязычной версии краткого опросника восприятия болезни. Психологические исследования. 2017; 10 (51): 1–14. DOI: 10.54359/ps.v10i51.407.Yaltonskiy V., Yaltonskaya A., Sirota N., Moskovchenko D. [Psychometric characteristics of the Russian-language version of the short questionnaire on disease perception]. Psikhologicheskie issledovaniya. 2017; 10 (51): 1–14. DOI: 10.54359/ps.v10i51.407 (in Russian).World Health Organization. Technical package for cardiovascular disease management in primary health care. Healthy-lifestyle counselling. Geneva: World Health Organization; 2018. Available at: https://iris.who.int/bitstream/handle/10665/260422/WHO-NMH-NVI18.1-eng.pdf;jsessionid=32900CB2DAF29876AA8FD97FCC5D2710?sequence=1 [Accessed: December 12, 2024].World Health Organization. Technical package for cardiovascular disease management in primary health care. Healthy-lifestyle counselling. Geneva: World Health Organization; 2018. Available at: https://iris.who.int/bitstream/handle/10665/260422/WHO-NMH-NVI18.1-eng.pdf;jsessionid=32900CB2DAF29876AA8FD97FCC5D2710?sequence=1 [Accessed: December 12, 2024].Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648. DOI: 10.1136/bmj.1.6077.1645.Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1 (6077): 1645–1648. DOI: 10.1136/bmj.1.6077.1645.IPCRG. Henrichsen S.H. Desktop Helper No.4 – Helping patients quit tobacco. 3rd edn. 2019. Available at: https://www.ipcrg.org/desktophelpers/desktop-helper-no-4-helping-patients-quit-tobacco-3rd-edition [Accessed: December 12, 2024].IPCRG. Henrichsen S.H. Desktop Helper No.4 – Helping patients quit tobacco. 3rd edn. 2019. Available at: https://www.ipcrg.org/desktophelpers/desktop-helper-no-4-helping-patients-quit-tobacco-3rd-edition [Accessed: December 12, 2024].IPCRG. Tsiligianni I., Williams S. Desktop helper No.12 – COPD and mental health: holistic and practical guidance for primary care. 2022. Available at: https://www.ipcrg.org/dth12 [Accessed: December 12, 2024].IPCRG. Tsiligianni I., Williams S. Desktop helper No.12 – COPD and mental health: holistic and practical guidance for primary care. 2022. Available at: https://www.ipcrg.org/dth12 [Accessed: December 12, 2024].Pollok J., van Agteren J.E., Carson-Chahhoud K.V. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2018; 12 (12): CD012346. DOI: 10.1002/14651858.CD012346.pub2.Pollok J., van Agteren J.E., Carson-Chahhoud K.V. Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2018; 12 (12): CD012346. DOI: 10.1002/14651858.CD012346.pub2.Tsiligianni I., Kocks J., Tzanakis N. et al. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim. Care Respir. J. 2011; 20 (3): 257–268. DOI: 10.4104/pcrj.2011.00029.Tsiligianni I., Kocks J., Tzanakis N. et al. Factors that influence disease-specific quality of life or health status in patients with COPD: a review and meta-analysis of Pearson correlations. Prim. Care Respir. J. 2011; 20 (3): 257–268. DOI: 10.4104/pcrj.2011.00029.Spathis A., Booth S., Moffat C. et al. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim. Care Respir. Med. 2017; 27 (1): 27. DOI: 10.1038/s41533-017-0024-z.Spathis A., Booth S., Moffat C. et al. The breathing, thinking, functioning clinical model: a proposal to facilitate evidence-based breathlessness management in chronic respiratory disease. NPJ Prim. Care Respir. Med. 2017; 27 (1): 27. DOI: 10.1038/s41533-017-0024-z.Berlin I., Covey L.S. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction. 2006; 101 (12): 1814–1821. DOI: 10.1111/j.1360-0443.2006.01616.x.Berlin I., Covey L.S. Pre-cessation depressive mood predicts failure to quit smoking: the role of coping and personality traits. Addiction. 2006; 101 (12): 1814–1821. DOI: 10.1111/j.1360-0443.2006.01616.x.Ho S.Y., Alnashri N., Rohde D. et al. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with chronic respiratory conditions. Gen. Hosp. Psychiatry. 2015; 37 (5): 399–407. DOI: 10.1016/j.genhosppsych.2015.05.002.Ho S.Y., Alnashri N., Rohde D. et al. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with chronic respiratory conditions. Gen. Hosp. Psychiatry. 2015; 37 (5): 399–407. DOI: 10.1016/j.genhosppsych.2015.05.002.Lou P., Chen P., Zhang P. et al. Effects of smoking, depression, and anxiety on mortality in COPD patients: a prospective study. Respir. Care. 2014; 59 (1): 54–61. DOI: 10.4187/respcare.02487.Lou P., Chen P., Zhang P. et al. Effects of smoking, depression, and anxiety on mortality in COPD patients: a prospective study. Respir. Care. 2014; 59 (1): 54–61. DOI: 10.4187/respcare.02487.Tønnesen P. Smoking cessation and COPD. Eur. Respir. Rev. 2013; 22 (127): 37–43. DOI: 10.1183/09059180.00007212.Tønnesen P. Smoking cessation and COPD. Eur. Respir. Rev. 2013; 22 (127): 37–43. DOI: 10.1183/09059180.00007212.Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316. DOI: 10.1586/17476348.1.3.307.Moretti M. Pharmacology and clinical efficacy of erdosteine in chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 2007; 1 (3): 307–316. DOI: 10.1586/17476348.1.3.307.Авдеев С.Н., Трушенко Н.В., Чикина С.Ю., Суворова О.А. Возможности терапии эрдостеином в снижении частоты обострений хронической обструктивной болезни легких. Пульмонология. 2022; 32 (2): 253–259. DOI: 10.18093/0869-0189-2022-32-2-253-259.Avdeev S.N., Trushchenko N.V., Chikina S.Yu., Suvorova O.A. [Possibilities of erdostein therapy in reducing the frequency of exacerbations of chronic obstructive pulmonary disease]. Pul'monologiya. 2022; 32 (2): 253–259. DOI: 10.18093/0869-0189-2022-32-2-253-259 (in Russian).Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. DOI: 10.1183/13993003.00711-2017.Dal Negro R.W., Wedzicha J.A., Iversen M. et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. Eur. Respir. J. 2017; 50 (4): 1700711. DOI: 10.1183/13993003.00711-2017.IPCRG. Tsiligianni I., Hoines K., Jensen C. et al. Desktop helper No.10 – Rational use of inhaled medications for the patient with COPD and multiple comorbid conditions: Guidance for primary care. 2019. Available at: https://www.ipcrg.org/dth10 [Accessed: December 12, 2024].IPCRG. Tsiligianni I., Hoines K., Jensen C. et al. Desktop helper No.10 – Rational use of inhaled medications for the patient with COPD and multiple comorbid conditions: Guidance for primary care. 2019. Available at: https://www.ipcrg.org/dth10 [Accessed: December 12, 2024].

The authors declare that there are no conflicts of interest present.